Cohance Lifesciences Limited - Laporan Laba Rugi (TTM)

Cohance Lifesciences Limited
IN ˙ NSEI
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Cohance Lifesciences Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 8,391 9,353 10,097 10,353 10,989 12,155 13,202 13,952 13,726 13,348 13,403 13,491 13,017 11,678 10,514 9,345 9,612 10,485 11,976 12,588
Change (%) 11.47 7.95 2.53 6.14 10.62 8.61 5.68 -1.62 -2.75 0.41 0.65 -3.51 -10.29 -9.97 -11.11 2.85 9.09 14.22 5.11
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 3,503 3,809 4,372 4,581 4,911 5,551 5,741 5,979 5,937 5,850 5,882 5,796 5,343 4,825 3,716 4,074 4,071 3,903 3,757 2,993
Change (%) 8.76 14.76 4.79 7.20 13.03 3.42 4.15 -0.70 -1.46 0.55 -1.47 -7.81 -9.71 -22.97 9.61 -0.07 -4.13 -3.73 -20.34
% of Revenue 41.74 40.73 43.30 44.25 44.69 45.67 43.49 42.85 43.25 43.83 43.89 42.96 41.05 41.32 35.35 43.59 42.35 37.22 31.37 23.77
Gross Operating Profit 4,888 5,544 5,725 5,771 6,078 6,604 7,461 7,973 7,789 7,498 7,521 7,695 7,674 6,853 6,797 5,271 5,541 6,582 8,219 9,595
Change (%) 13.41 3.28 0.80 5.30 8.67 12.97 6.86 -2.31 -3.74 0.31 2.31 -0.27 -10.70 -0.82 -22.45 5.11 18.79 24.86 16.75
% of Revenue 58.26 59.27 56.70 55.75 55.31 54.33 56.51 57.15 56.75 56.17 56.11 57.04 58.95 58.68 64.65 56.41 57.65 62.78 68.63 76.23
SG&A 874 934 784 821 844 881 1,024 1,078 1,133 1,179 1,218 1,127 1,126 1,158 1,396 1,552 1,761 2,046 2,562 2,870
Change (%) 6.78 -16.01 4.74 2.76 4.34 16.25 5.30 5.06 4.12 3.25 -7.46 -0.06 2.80 20.59 11.17 13.49 16.19 25.22 12.01
% of Revenue 10.42 9.98 7.77 7.93 7.68 7.24 7.75 7.73 8.25 8.83 9.08 8.35 8.65 9.91 13.28 16.61 18.32 19.52 21.39 22.80
R&D -11 -12 111 103 102 97 104 102 86 87 84 108 109
Change (%) 2.90 -1,043.15 -6.57 -1.40 -4.61 6.57 -1.16 -15.58 0.94 28.42 0.11
% of Revenue -0.14 -0.13 1.10 1.00 0.93 0.80 0.78 0.73 0.63 0.65 0.63 0.83 0.93
OpEx 4,985 5,394 5,998 6,243 6,657 7,354 7,786 8,198 8,220 8,252 8,141 8,152 7,697 7,178 6,970 6,686 6,949 7,382 8,695 9,880
Change (%) 8.20 11.21 4.08 6.63 10.47 5.88 5.30 0.26 0.39 -1.34 0.13 -5.59 -6.74 -2.90 -4.07 3.93 6.23 17.79 13.63
% of Revenue 59.41 57.66 59.41 60.30 60.58 60.50 58.97 58.76 59.88 61.82 60.74 60.43 59.13 61.46 66.29 71.55 72.30 70.40 72.60 78.49
Operating Income 3,406 3,960 4,099 4,110 4,332 4,802 5,416 5,754 5,506 5,096 5,262 5,338 5,321 4,500 3,544 2,659 2,663 3,103 3,281 2,708
Change (%) 16.25 3.52 0.26 5.41 10.84 12.80 6.23 -4.30 -7.46 3.26 1.46 -0.33 -15.42 -21.25 -24.97 0.14 16.54 5.72 -17.47
% of Revenue 40.59 42.34 40.59 39.70 39.42 39.50 41.03 41.24 40.12 38.18 39.26 39.57 40.87 38.54 33.71 28.45 27.70 29.60 27.40 21.51
Interest Expense -181 -133 -91 -85 -71 -59 -62 -56 -47 -53 -128 -51 -53 -52 -74 -72 -77 -89 -124 -123
Change (%) -26.87 -31.08 -6.50 -17.17 -16.50 5.39 -10.82 -15.87 13.71 140.97 -59.95 4.08 -2.13 42.53 -3.48 7.51 15.13 38.75 -0.16
% of Revenue -2.16 -1.42 -0.91 -0.83 -0.64 -0.49 -0.47 -0.40 -0.34 -0.40 -0.96 -0.38 -0.41 -0.45 -0.71 -0.77 -0.80 -0.85 -1.03 -0.98
Net Income 2,977 3,534 3,623 3,759 3,988 4,453 4,538 4,563 4,313 3,790 4,113 4,243 4,318 3,709 3,003 2,405 2,431 2,792 2,679 2,414
Change (%) 18.72 2.53 3.74 6.09 11.65 1.92 0.54 -5.46 -12.14 8.52 3.17 1.77 -14.12 -19.04 -19.92 1.11 14.86 -4.07 -9.89
% of Revenue 35.48 37.78 35.89 36.31 36.29 36.63 34.37 32.70 31.42 28.39 30.69 31.45 33.17 31.76 28.56 25.73 25.29 26.63 22.37 19.18

Source: Capital IQ

Other Listings
IN:543064
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista